Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI 906 Plus Erlotinib (Tarceva®), or Erlotinib Plus Placebo in Patients With Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC.
ON
Oshawa
Ottawa
Toronto
QC
Jewish General Hospital, Montreal
Royal Victoria Hospital, Montreal
Montreal General Hospital, Montreal
3. Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)
ClinicalTrials.gov Identifier: NCT00676507
Rationale: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. It is not yet known whether vaccine therapy is more effective than a placebo as maintenance therapy in treatment of subjects with non-small cell lung cancer.
Purpose: This randomized phase III trial is studying vaccine therapy to compare the overall survival of subjects with stage III or IV non-small cell lung cancer treated with belagenpumatucel-L (Lucanix™) vs placebo.
ON
Princess Margaret Hospital, Toronto
AB
Cross Cancer Institute, Edmonton
4. Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov Identifier: NCT01137968
The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4 cycles of platinum based therapy.
Participants will be randomized in a 2:1 ratio to imetelstat + standard of care versus standard of care alone. Participants who received bevacizumab with their induction chemotherapy will continue to receive bevacizumab on this study.
QC
Hopital Charles Lemoyne, Greenfield Park
Hopital Notre Dame, Montreal